Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.
Uricoli B, Birnbaum LA, Do P, Kelvin JM, Jain J, Costanza E, Chyong A, Porter CC, Rafiq S, Dreaden EC. Uricoli B, et al. Among authors: birnbaum la. Adv Healthc Mater. 2021 Aug;10(15):e2002214. doi: 10.1002/adhm.202002214. Epub 2021 Mar 9. Adv Healthc Mater. 2021. PMID: 33690997 Free PMC article. Review.
Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM, Chimenti ML, Zhang DY, Williams EK, Moore SG, Humber GM, Baxter TA, Birnbaum LA, Qui M, Zecca H, Thapa A, Jain J, Jui NT, Wang X, Fu H, Du Y, Kemp ML, Lam WA, Graham DK, DeRyckere D, Dreaden EC. Kelvin JM, et al. Among authors: birnbaum la. J Control Release. 2023 Sep;361:470-482. doi: 10.1016/j.jconrel.2023.07.045. Epub 2023 Aug 14. J Control Release. 2023. PMID: 37543290 Free PMC article.
Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
Kelvin JM, Jain J, Thapa A, Qui M, Birnbaum LA, Moore SG, Zecca H, Summers RJ, Switchenko JM, Costanza E, Uricoli B, Wang X, Jui NT, Fu H, Du Y, DeRyckere D, Graham DK, Dreaden EC. Kelvin JM, et al. Among authors: birnbaum la. Pharm Res. 2023 Sep;40(9):2133-2146. doi: 10.1007/s11095-023-03596-9. Epub 2023 Sep 13. Pharm Res. 2023. PMID: 37704893
Door to needle time trends after transition to tenecteplase: A Multicenter Texas stroke registry.
Rodriguez N, Prasad S, Olson DM, Bandela S, Gealogo Brown G, Kwon Y, Gebreyohanns M, Jones EM, Ifejika NL, Stone S, Anderson JA, Savitz SI, Cruz-Flores S, Warach SJ, Goldberg MP, Birnbaum LA. Rodriguez N, et al. Among authors: birnbaum la. J Stroke Cerebrovasc Dis. 2024 Aug;33(8):107774. doi: 10.1016/j.jstrokecerebrovasdis.2024.107774. Epub 2024 May 23. J Stroke Cerebrovasc Dis. 2024. PMID: 38795796
Combination Treatment of Recurrent Basilar Tip and Anterior Communicating Aneurysms With Transcirculation P1-P1 and Y Stenting Techniques: 2-Dimensional Operative Video.
Gaub M, Pathuri S, Gunaji R, Lafuente M, Birnbaum LA, Al Saiegh F, Mascitelli JR. Gaub M, et al. Among authors: birnbaum la. Oper Neurosurg (Hagerstown). 2023 Dec 4. doi: 10.1227/ons.0000000000001022. Online ahead of print. Oper Neurosurg (Hagerstown). 2023. PMID: 38047641 No abstract available.
Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.
Kelvin JM, Jain J, Thapa A, Qui M, Birnbaum LA, Moore SG, Zecca H, Summers RJ, Costanza E, Uricoli B, Wang X, Jui NT, Fu H, Du Y, DeRyckere D, Graham DK, Dreaden EC. Kelvin JM, et al. Among authors: birnbaum la. bioRxiv [Preprint]. 2023 Mar 15:2023.03.13.531236. doi: 10.1101/2023.03.13.531236. bioRxiv. 2023. Update in: Pharm Res. 2023 Sep;40(9):2133-2146. doi: 10.1007/s11095-023-03596-9 PMID: 36993676 Free PMC article. Updated. Preprint.
30 results